ONC 206
Alternative Names: ONC-206Latest Information Update: 17 Jul 2024
Price :
$50 *
At a glance
- Originator Oncoceutics
- Developer Chimerix; Oncoceutics
- Class Antineoplastics; Benzyl compounds; Imidazoles; Pyridones; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Endopeptidase Clp stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioma
- Preclinical Glioblastoma; Liver cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
- No development reported CNS cancer
Most Recent Events
- 31 May 2024 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours including prostate cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Preclinical trials in Glioblastoma in USA (PO) before April 2024